Life sciences and healthcare enterprises represent the biggest market in the United States economy. Provided the value of this sector, there is enhancing need for monetary evaluation of both openly and independently held business.
At the very same time, precise evaluation is especially hard because of moving company designs, the existing economy, copyright rights concerns, constant development in the sector, altering population demographics, quality problems, and federal government participation in healthcare policy, conversation, and argument. Herein, we analyze the altering and progressively troublesome evaluation of life sciences and healthcare enterprises that have apparent value from a social well-being point of view.
The Brave New World of Valuing Life Sciences and Healthcare Enterprises case solution
PUBLICATION DATE: March 15, 2010 PRODUCT #: BH379-PDF-ENG
This is just an excerpt. This case is about TECHNOLOGY & OPERATIONS
Related Case Solutions & Analyses:
Ahold: Royal Dutch Disaster
CIBC-Barclays: Should Their Caribbean Operations Be Merged
Toy World Inc.: An Operations Perspective
Laidlaw: The Resignation of James R. Bullock
Mars Incorporated Online Procurement
Is Your Business Ready for a Digital Future?
Bridging the CIO-CEO gap: It takes two to tango
Semiconductor Manufacturing International Company in 2011
PQI: Management of Suppliers
Blogs at Dresdner Kleinwort Wasserstein: (A), Portuguese Version
